Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease

HomeCirculationVol. 149, No. 16Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull TextAccelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease Brendon L. Neuen, Katherine R. Tuttle and Muthiah Vaduganathan Brendon L. NeuenBrendon L. Neuen Correspondence to: Brendon L. Neuen, MBBS(Hons), MSc, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia 2050. Email E-mail Address: [email protected] https://orcid.org/0000-0001-9276-8380 The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N.). Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.). Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.L.N., M.V.). , Katherine R. TuttleKatherine R. Tuttle https://orcid.org/0000-0002-2235-0103 University of Washington and Providence Medical Research Center, Providence Health Care, Spokane (K.R.T.). and Muthiah VaduganathanMuthiah Vaduganathan https://orcid.org/0000-0003-0885-1953 Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.L.N., M.V.). Originally published15 Apr 2024https://doi.org/10.1161/CIRCULATIONAHA.123.068524Circulation. 2024;149:1238–1240FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1240.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Brendon L. Neuen, MBBS(Hons), MSc, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia 2050. Email bneuen@georgeinstitute.org.auREFERENCES1. Rossing P, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int. 2022; 102:S1–S127. doi: 10.1016/j.kint.2022.06.008CrossrefMedlineGoogle Scholar2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2022; 45:2753–2786. doi: 10.2337/dci22-0034CrossrefMedlineGoogle Scholar3. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the Task Force on the Management of Cardiovascular Disease in Patients With Diabetes of the European Society of Cardiology (ESC).Eur Heart J. 2023; 44:4043–4140. doi: 10.1093/eurheartj/ehad192CrossrefMedlineGoogle Scholar4. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.Lancet. 2022; 400:1938–1952. Doi: 10.1016/S0140-6736(22)02076-1CrossrefMedlineGoogle Scholar5. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive model for progression of chronic kidney disease to kidney failure.JAMA. 2011; 305:1553–1559. doi: 10.1001/jama.2011.451CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails April 16, 2024Vol 149, Issue 16 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.068524PMID: 38620082 Originally publishedApril 15, 2024 PDF download Advertisement SubjectsCardiorenal SyndromeCardiovascular DiseaseDiabetes, Type 2Metabolic SyndromeMortality/Survival